R&D | Cutting-edge science and innovative research

R&D

Agentic AI and the human element: Building trustworthy autom...

The future of clinical trials isn’t about replacing people. It’s about empowering them with smarter tools.

News

Boehringer bets up to $500m on Sitryx immunology programme

Boehringer Ingelheim's partnership with Sitryx is focused on a family of small-molecule drugs for autoimmune and inflammatory diseases.

News

Head to head figurine fights, red and blue

Lilly says orforglipron tops Wegovy pill in diabetes trial

Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral Wegovy in type 2 diabetes raises as many questions as it answers.

News

Asahi Kasei buys antiviral firm Aicuris for €780m

Asahi Kasei has agreed to buy Germany's Aicuris for around $920m, adding an antiviral drug it hopes will help drive its 2030 pharma sales to $1.9bn.

News

Changes at the top of Sarepta, Alkermes, as CEOs depart

Two long-serving pharma CEOs have announced their departures, as Sarepta's Doug Ingram and Alkermes' Richard Pops announce their retirement.

R&D

Automation of literature search and review

Over the years, pharmacovigilance (PV) processes have relied on PV professionals manually sifting through large volumes of data to identify, assess, and report Adverse Event (AE) informatio

R&D

Transitioning from traditional surgical methods to the innov...

Patient lives are being transformed by a transitioning from traditional surgical methods to the innovative use of stem cells.

News

Novo Nordisk looks set to add another string to Ozempic bow

Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabete

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

Webinars

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Boehringer bets up to $500m on Sitryx immunology programme

Boehringer Ingelheim's partnership with Sitryx is focused on a family of small-molecule drugs for autoimmune and inflammatory diseases.

News

Lilly says orforglipron tops Wegovy pill in diabetes trial

Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral Wegovy in type 2 diabetes raises as many questions as it answers.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

Agentic AI and the human element: Building trustworthy autom...

The future of clinical trials isn’t about replacing people. It’s about empowering them with smarter tools.

R&D

Hexagonal rendering of AI concept on dark blue background

Results, reality, and recalibration: Unpacking AI hype at SC...

SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.

R&D

Why the government’s latest funding push is critical to the ...

Many of the UK’s most promising life sciences innovations continue to face persistent funding challenges, made worse by an increasingly volatile globa

Deep Dive

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

Beyond obesity: How GLP-1s are changing the game for hundred...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

JPM2026 wrap-up with Nicole Raleigh and Jonah Comstock

On JPM2026 and healthcare investment today, with Jonah Comst...

Editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to discuss JPM2026.

R&D

pharmaphorum podcast Episode 239, Dr Jorg Schuttrumpf

Shaping the future of immunodeficiency care, with Dr Jörg Sc...

Dr Jörg Schüttrumpf, Chief Scientific Innovation Officer of Grifols, discusses advancing immunoglobulin (or IG) treatment for immune disorders.

R&D

pharmaphorum podcast Episode 235, Markus Vossman, Illumina

On genomics, NGS, and doing much more good than bad, with Ma...

Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.

Video

R&D

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.

R&D

The long-delayed promise of the microbiome, with Sam Possemi...

Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.

R&D

Allogeneic cell therapy isn’t dead, with Brian Culley

Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.

White Papers

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

R&D

Life Sciences Industry Report - Part 7 cover image

Life Sciences Industry Report - Biologics and Generics

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

R&D

Life Sciences Industry Report - Rare Disease Space

There are some 7,000 known rare diseases in the world, yet, multiple challenges and unmet needs remain when it comes to therapies for these diseases.

Event

Partner Content

7th Dermatology Drug Development Summit Europe

The Summit is a premier three-day industry event designed for senior leaders, clinical scientists, regulatory experts and commercial strategists

R&D

Partner Content

Emerging Trends in Personalised Medicine at PHARMAP 2026

The Pharmaceutical Manufacturing & Packaging Congress is an exclusive annual event that fosters networking and knowledge-sharing among professionals

Partner Content

The Pharmaceutical Manufacturing and Packaging Congress (PHA...

The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2026 unites professionals to discuss the most recent trends of industry in Amsterdam

Partner Content

Event

Partner Content

7th Dermatology Drug Development Summit Europe

The Summit is a premier three-day industry event designed for senior leaders, clinical scientists, regulatory experts and commercial strategists

R&D

Partner Content

Emerging Trends in Personalised Medicine at PHARMAP 2026

The Pharmaceutical Manufacturing & Packaging Congress is an exclusive annual event that fosters networking and knowledge-sharing among professionals

Partner Content

The Pharmaceutical Manufacturing and Packaging Congress (PHA...

The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2026 unites professionals to discuss the most recent trends of industry in Amsterdam

Agentic AI and the human element: Building trustworthy autom...

Boehringer bets up to $500m on Sitryx immunology programme

Lilly says orforglipron tops Wegovy pill in diabetes trial

Asahi Kasei buys antiviral firm Aicuris for €780m

Changes at the top of Sarepta, Alkermes, as CEOs depart

Automation of literature search and review

Transitioning from traditional surgical methods to the innov...

Novo Nordisk looks set to add another string to Ozempic bow

Synthetic control arms in clinical trials: Making it happen

How synthetic control arms are changing clinical trials

Boehringer bets up to $500m on Sitryx immunology programme

Lilly says orforglipron tops Wegovy pill in diabetes trial

Touring Chiesi's vision for the future at the new Biotech Ce...

Vir awarded $1 billion multi-year BARDA influenza contract

Agentic AI and the human element: Building trustworthy autom...

Results, reality, and recalibration: Unpacking AI hype at SC...

Why the government’s latest funding push is critical to the ...

The GLP-1 Reckoning

Designing obesity trials around real lives: How patient cent...

Beyond obesity: How GLP-1s are changing the game for hundred...

Exploring the future: Opportunities and challenges in cell a...

Beyond clinical: Boosting recruitment and retention with SDO...

The evolution of clinical research: Embracing new delivery m...

On JPM2026 and healthcare investment today, with Jonah Comst...

Shaping the future of immunodeficiency care, with Dr Jörg Sc...

On genomics, NGS, and doing much more good than bad, with Ma...

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

The long-delayed promise of the microbiome, with Sam Possemi...

Allogeneic cell therapy isn’t dead, with Brian Culley

A New Framework to Engineer Breakthrough Value for Medicines

Life Sciences Industry Report - Biologics and Generics

Life Sciences Industry Report - Rare Disease Space

7th Dermatology Drug Development Summit Europe

Emerging Trends in Personalised Medicine at PHARMAP 2026

The Pharmaceutical Manufacturing and Packaging Congress (PHA...

7th Dermatology Drug Development Summit Europe

Emerging Trends in Personalised Medicine at PHARMAP 2026

The Pharmaceutical Manufacturing and Packaging Congress (PHA...

Eisai unveils digital platform for kidney cancer patients

Using AI-driven synthetic personas to take your insights fur...

Debates & Insights

News

Press Releases

Editor's Picks

Views & Analysis

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Partner Content

Editor's Picks